ENVERIC BIOSCIENCES, INC. Stock-Based Compensation
ENVERIC BIOSCIENCES, INC. (ENVB) reported Stock-Based Compensation of $213.79 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $125.11K, a 39.34% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $88.67K, a 54.26% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $240.23K, a 49.07% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $186.98K, a 49.41% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $827.32K, a 47.05% decline from fiscal 2024.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $1.56M, a 27.34% decline from fiscal 2023.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $2.15M, a 17.95% decline from fiscal 2022.
- ENVERIC BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $2.62M, a 79.20% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $125.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $213.79K 10-Q · filed 2026-08-14 | $454.02K derived: sum of 3 quarters · filed 2026-08-14 | $641.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $88.67K 10-Q · filed 2026-05-15 | $328.91K derived: sum of 2 quarters · filed 2026-05-15 | $515.89K derived: sum of 3 quarters · filed 2026-05-15 | $722.15K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $240.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $427.21K derived: sum of 2 quarters · filed 2026-03-27 | $633.48K derived: sum of 3 quarters · filed 2026-08-14 | $827.32K 10-K · filed 2026-03-27 |
| 2025-09-30 | $186.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $393.24K derived: sum of 2 quarters · filed 2026-08-14 | $587.09K 10-Q · filed 2025-11-14 | $1.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $206.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $400.11K 10-Q · filed 2026-08-14 | $871.78K derived: sum of 3 quarters · filed 2026-08-14 | $1.24M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $193.85K 10-Q · filed 2026-05-15 | $665.52K derived: sum of 2 quarters · filed 2026-05-15 | $1.04M derived: sum of 3 quarters · filed 2026-05-15 | $1.40M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $471.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $841.29K derived: sum of 2 quarters · filed 2026-03-27 | $1.21M derived: sum of 3 quarters · filed 2026-03-27 | $1.56M 10-K · filed 2026-03-27 |
| 2024-09-30 | $369.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $739.23K derived: sum of 2 quarters · filed 2025-11-14 | $1.09M 10-Q · filed 2025-11-14 | $1.46M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $369.61K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $721.10K 10-Q · filed 2025-08-14 | $1.09M derived: sum of 3 quarters · filed 2025-08-14 | $1.46M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $351.49K 10-Q · filed 2025-05-14 | $716.22K derived: sum of 2 quarters · filed 2025-05-14 | $1.09M derived: sum of 3 quarters · filed 2025-05-14 | $1.97M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $364.73K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $737.59K derived: sum of 2 quarters · filed 2025-03-28 | $1.62M derived: sum of 3 quarters · filed 2025-03-28 | $2.15M 10-K · filed 2025-03-28 |
| 2023-09-30 | $372.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.25M derived: sum of 2 quarters · filed 2024-11-14 | $1.79M 10-Q · filed 2024-11-14 | $2.31M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $879.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.41M 10-Q · filed 2024-08-12 | $1.94M derived: sum of 3 quarters · filed 2024-08-12 | $2.59M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $532.84K 10-Q · filed 2024-05-15 | $1.06M derived: sum of 2 quarters · filed 2024-05-15 | $1.71M derived: sum of 3 quarters · filed 2024-05-15 | $2.38M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $529.37K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $1.17M derived: sum of 2 quarters · filed 2024-03-26 | $1.85M derived: sum of 3 quarters · filed 2024-03-26 | $2.62M 10-K · filed 2024-03-26 |
| 2022-09-30 | $645.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.32M derived: sum of 2 quarters · filed 2023-11-13 | $2.09M 10-Q · filed 2023-11-13 | $9.86M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $677.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.45M 10-Q · filed 2023-08-11 | $9.21M derived: sum of 3 quarters · filed 2023-08-11 | $9.70M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $768.62K 10-Q · filed 2023-05-15 | $8.54M derived: sum of 2 quarters · filed 2023-06-09 | $9.02M derived: sum of 3 quarters · filed 2023-06-09 | $9.77M derived: sum of 4 quarters · filed 2023-06-09 |
| 2021-12-31 | $7.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-09 | $8.25M derived: sum of 2 quarters · filed 2023-06-09 | $9.01M derived: sum of 3 quarters · filed 2023-06-09 | $12.60M 10-K/A · filed 2023-06-09 |
| 2021-09-30 | $486.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.24M derived: sum of 2 quarters · filed 2022-11-14 | $4.83M 10-Q · filed 2022-11-14 | $6.76M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $750.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $4.34M 10-Q · filed 2022-08-12 | $6.27M derived: sum of 3 quarters · filed 2022-08-12 | $6.29M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $3.59M 10-Q · filed 2022-05-13 | $5.52M derived: sum of 2 quarters · filed 2022-05-13 | $5.53M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-01 | $1.94M derived: sum of 2 quarters · filed 2021-04-01 | $1.98M 10-K · filed 2021-04-01 | |
| 2020-09-30 | $14.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $49.47K 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $34.64K 10-Q · filed 2020-08-14 | |||
| 2019-12-31 | $124.05K derived: 10-K 12 month − 10-Q 9 month · filed 2021-04-01 | $124.05K derived: sum of 2 quarters · filed 2021-04-01 | $624.05K 10-K · filed 2021-04-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $500.00K 10-Q · filed 2020-11-16 | ||
| 2019-06-30 | $500.00K 10-Q · filed 2020-08-14 | |||
| 2017-12-31 | $7.08M 10-K · filed 2018-04-02 | |||
| 2016-12-31 | $1.46M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |